NCT06658951View on ClinicalTrials.gov

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
HER2-positive Advanced Malignant Solid Tumors
Interventions
BIOLOGICAL

Anti-HER2 CAR-T cells

All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

UTC Therapeutics Inc.

INDUSTRY